Sanofi Aktie - SAN

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

91,28

Gebot

90,68

Fragen

91,66

Volumen

4.412.378

89,93 Tagesbereich 91,62

84,93 52-Wochen-Bereich 106,14

Marktkapitalisierung

114,341B

Handelsende

91,50

Handelsbeginn

90,89

Letzte Trade

150

91.28

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

1.534.807

Ausgegebene Aktien

1.252.640.466

Dividendenrendite

12.14%

Kurs-Gewinn-Verhältnis

21,17

Gewinn pro Aktie (EPS)

4,31

Erlöse

43,07B

Nettogewinn

5,4B

Sektor

Health & Allied Services,nec

Branche

Pharmaceutical Preparations

Website

www.sanofi.com

Hauptsitz

Paris, Paris, Fra

Gegründet

1994

Sanofi is listed in the Health & Allied Services sector of the Euronext with ticker SAN. The last closing price for Sanofi was 91,50 €. Over the last year, Sanofi shares have traded in a share price range of 84,93 € to 106,14 €.

Sanofi currently has 1.252.640.466 shares in issue. The market capitalisation of Sanofi is 114,62 € billion. Sanofi has a price to earnings ratio (PE ratio) of 21.17.

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to...

Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi

Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Paris, le 19 décembre 2024. Le Conseil...

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025...

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Duvakitug positive phase 2b results demonstrate best-in-class...

Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de...

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the...

Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées

Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées Le...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.86	0.951117009511	90.42	93.29	87.5	2364130	90.79275156	DE
4	-0.52	-0.566448801743	91.8	93.42	87.5	1618973	91.52573691	DE
12	-10.54	-10.3516008643	101.82	104.46	87.5	1534807	95.69159524	DE
26	4.26	4.89542633877	87.02	106.14	86.71	1519117	96.40787764	DE
52	2.17	2.43519245876	89.11	106.14	84.93	1443789	93.29333152	DE
156	5.62	6.56082185384	85.66	106.66	76.45	1737311	92.71328949	DE
260	1.18	1.30965593785	90.1	106.66	67.65	1943101	89.40337895	DE

SAN - Frequently Asked Questions (FAQ)

What is the current Sanofi share price?

The current share price of Sanofi is 91,28 €

How many Sanofi shares are in issue?

Sanofi has 1.252.640.466 shares in issue

What is the market cap of Sanofi?

The market capitalisation of Sanofi is EUR 114,62B

What is the 1 year trading range for Sanofi share price?

Sanofi has traded in the range of 84,93 € to 106,14 € during the past year

What is the PE ratio of Sanofi?

The price to earnings ratio of Sanofi is 21,17

What is the cash to sales ratio of Sanofi?

The cash to sales ratio of Sanofi is 2,65

What is the reporting currency for Sanofi?

Sanofi reports financial results in EUR

What is the latest annual turnover for Sanofi?

The latest annual turnover of Sanofi is EUR 43,07B

What is the latest annual profit for Sanofi?

The latest annual profit of Sanofi is EUR 5,4B

What is the registered address of Sanofi?

The registered address for Sanofi is 46, AVENUE DE LA GRANDE ARMEE, PARIS, PARIS, 75017

What is the Sanofi website address?

The website address for Sanofi is www.sanofi.com

Which industry sector does Sanofi operate in?

Sanofi operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
TMBSZTME Pharma NV	0,02 € (185,71%)	132,5k
MLGEQGentlemen S Equity SA	0,0175 € (118,75%)	1,14k
ALCYBCybergun	0,0002 € (100,00%)	17,54M
MLAAHAmatheon Agri Holding NV	0,0185 € (54,17%)	40,1k
ALARFAdeunis	0,94 € (28,77%)	5,27k
MLSMLSmalto	0,0125 € (-37,50%)	2,34k
MLFTIFrance Tourisme Immobilier	0,025 € (-35,90%)	56,77k
CNVCnova NV	0,209 € (-19,62%)	26,38k
MLWEAWeaccess Group	0,382 € (-16,96%)	5,95k
ALEUPEuroplasma	0,0353 € (-15,95%)	3,16M
ATOAtos SE	0,0021 € (0,00%)	2,71B
BCPBanco Comercial Portugues SA	0,4493 € (-0,69%)	66,54M
ALHGLouis Hachette Group	1,3342 € (4,87%)	52,04M
KPNKoninklijke KPN NV	3,509 € (-1,21%)	26,9M
VIVVivendi SE	2,51 € (2,41%)	26,39M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Sanofi (SAN)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Sanofi

SAN Neueste Nachrichten

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: Availability of the Q4 2024 Aide-mémoire

Communiqué de presse : Mise en ligne du document « Q4 2024 Aide-mémoire »

Press Release: Availability of the Q4 2024 Aide-mémoire

Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Press Release: Availability of the Q4 2024 Aide-mémoire

Communiqué de presse : Mise en ligne du document « Q4 2024 Aide-mémoire »

SAN - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Sanofi (SAN) Börsenkurse

Sanofi (SAN)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Sanofi

SAN Neueste Nachrichten

SAN - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen